

RESEARCH ARTICLE

Genetic identification of methicillin resistant *Staphylococcus aureus* (MRSA) isolated from diabetic foot ulcers and evaluating the inhibition activity of reuterin against this bacteria

Khulood Abdulkareem Hussein¹, Abdulmutalib Abdulla Mohammed², Sundus Baqer Dawood³, Sajjad Salim Issa⁴

Abstract

Objective: To genetically diagnose the isolates of methicillin-resistant *Staphylococcus aureus* taken from patients with severe diabetic foot infections, and to test the inhibitory effect of reuterin on the growth of these bacteria.

Method: The experimental study was conducted from June to November 2021 at the Diabetes Unit of Al-Faihaa General Hospital, Basrah, Iraq, and comprised 62 foot ulcer swabs from the necrotic lesions of patients with type 2 diabetes. The swabs were cultivated first in brain heart infusion broth media, and then streaked on Mannitol salt agar and *Staphylococcus* chromogenic agar media for phenotypic and genetic analysis. The genetic identification of bacteria was confirmed by deoxyribonucleic acid extraction, and methicillin-resistant *Staphylococcus aureus* was confirmed by the presence of plasmid *mecA* gene. The inhibition activity of reuterin towards methicillin-resistant *Staphylococcus aureus* was determined using the minimum inhibitory concentration test. All data was analyzed with SPSS version 23.

Results: A total of 62 swabs were taken from the necrotic lesions of type 2 diabetes mellitus (T2DM) patients with diabetic foot ulcers. Of the total isolates, 9(14.5%) gave mauve to purple colour on *Staphylococcus* chromogenic agar, which was then genetically confirmed as methicillin-resistant *Staphylococcus aureus*. The minimum inhibitory concentration value of these bacteria was 10µl/ml at 16mm inhibition zone diameter. There was no cytotoxicity of reuterin to human red blood cells.

Conclusion: Reuterin was found to be a natural antimicrobial substance suitable for use to disinfect diabetic foot wounds from bacterial contamination and infection, especially those caused by methicillin-resistant *Staphylococcus aureus*.

Key Words: Methicillin, *Staphylococcus aureus*, Agar, Diabetic, hydroxypropionaldehyde, Microbial Sensitivity, Mannitol, DNA, Erythrocytes, Plasmids, Brain

(JPMA 74: S132 (Supple-8); 2024) DOI:<https://doi.org/10.47391/JPMA-BAGH-16-29>

Introduction

Diabetic foot infections (DFIs) are inflammation of the thin tissues or bones located beneath the malleoli. They usually start with skin ulcers in about 25% of cases, spreading contiguously from the skin to the deep subcutaneous tissue and/or bone. These infections are often complicated by contagion microbial pathogens, and *Staphylococcus* (*S.*) *aureus* is the most causative factor which is associated with previous antibiotic treatments and a long recovery time¹. The need for amputation and surgical debridement increases in patients infected with this bacteria which may be minor or significant. The prevalence of methicillin-resistant *S. aureus* (MRSA) strain in DFIs is 15-30% and there is a worrying trend of increase in several countries, with some studies identifying new strains of MRSA distinctive by the

presence of *mecA* gene that confers resistance to methicillin antibiotic. These strain also have mobile genetic elements (MGEs) that are composed of 15-25% of the genome, including plasmids, transposons, pathogenicity islands, prophages and integrons. An understanding of MGEs is essential to increase human knowledge on the genetic drivers of antibiotic resistance (AR)².

S. aureus is a gram-positive bacteria and facultative anaerobe occurring naturally on the human skin and in the nasal passages. This bacterium is toxic, and one of the effects of its toxin is to reduce the effectiveness of antibiotics. Besides, exfoliative toxins facilitate bacterial invasion of the host skin³. Methicillin, the first synthetic penicillin in 1960, was used to treat *S. aureus* infections, but soon many methicillin-resistant strains appeared in hospitals². Two main classes of MRSA strain have been found. The first is known as nosocomial infections that are often transmitted in healthcare settings and are also called hospital-acquired MRSA (HA-MRSA). The second

¹⁻³Department of Fundamental Medical Science, University of Basrah, Basrah, Iraq. ⁴Department of Community Health, University of Basrah, Basrah, Iraq.

Correspondence: Khulood Abdulkareem Hussein

Email: khulood.altameemi@uobasrah.edu.iq

class is known as community-acquired MRSA (CA-MRSA). Diabetic patients may get both kinds of infections due to frequent sores and ulceration⁴. The moderate-severity CA-MRSA can be treated with co-trimoxazole (trimethoprim/sulfamethoxazole), doxycycline or clindamycin after susceptibility results are available, while both severe CA-MRSA and HA-MRSA infections must be treated with glycopeptides, linezolid or daptomycin².

Reuterin, a compound derived from lactobacillus (*L. reuteri*), is a useful material in sterilising biological tissues in healthcare or pharmaceutical applications⁵. It has a broad inhibitory spectrum towards most bacteria, including *S. aureus*. The inhibitory effect of reuterin comes from its ability to inactivate the bacterial proteins as well as small molecules that contain thiol groups and the primary amines⁶. Second, the dimmer shape of reuterin structure, which is similar to the structure of ribose sugar, can specifically inhibit the reductive ribonucleotide enzyme which is often required for the generation of deoxynucleotide that is necessary for synthesis of deoxyribonucleic acid (DNA) in bacteria⁷.

The increasing resistance to antibiotics, in particular methicillin and vancomycin, need to be further studied to assess the requirement for new antibiotics in the treatment of DFIs, and to evaluate the therapeutic approach to this problem. The current study was planned to genetically diagnose MRSA isolates taken from patients with severe DFIs, and to test the inhibitory effect of reuterin on the growth of these bacteria.

Materials and Methods

The experimental study was conducted from June to November 2021 at the Diabetes Unit of Al-Faihaa General Hospital, Basrah, Iraq. After approval from the institutional ethics review committee, the sample was raised using convenience sampling technique. Those included were patients type 2 diabetes mellitus (T2DM) with diabetic foot ulcers (DFUs). Swabs were taken from the necrotic lesions after taking informed consent from the patients. Those not willing to participate were excluded.

The swab samples were placed first in sterile tubes containing brain heart infusion broth (BHIB) (HiMedia, India), and then transported to the laboratory where they were incubated for 24h at 37°C. After the broths gave positive growth, they were inoculated by streaking method on Manitol salt agar (HiMedia, India) and MRSA staphylococcus chromogenic agar media (Conda/Pronadisa, Spain) and incubated for 24h at 37°C. The grown colonies were observed and microscopically examined after gram staining for the shape and assemblies of a cell, and then cultured using nutrient agar

(HiMedia, India) for another testing⁸.

DNA extraction was obtained using a genomic DNA mini-kit (Geneaid, Taiwan), according to the manufacturer's instructions.

The primers used for staphylococcus genus-specific included Staph 756F (5'-AACTCTGTTATTAGGGAAGAACA-3') and Staph 750R

(5'-CCACCTTCCTCCGGTTTGTACC-3')⁹. The *mecA* gene primers used to determine plasmid gene included MecA1 (5'-GTAGAAATGACTGAACGTCCGATAA-3') and MecA2 (5'-CCAATCCACATTGT TTCGGTCTAA-3')¹⁰.

Thermo-cycling conditions (TechneTC-300G,UK) for Staph 16S rRNA gene were set at 95°C for 5 min, followed by 35 cycles of 95°C for 30s, 55°C for 30s, 72°C for 1 min, and 72°C for 5 min. For *mecA* gene, the conditions were set at 3 min for 95°C followed by 30 cycles for 1 min at 94°C, 53°C for 30s, 72°C for 1 min, and 72°C for 6 min.

The reuterin activity was quantified by the determination of the minimum inhibitory concentration (MIC) towards MRSA using the well-diffusion method on Mueller-Hinton agar (MHA)^{11,12}. Concentrations of standard reuterin included 1µl, 5µl, 10µl, 20µl, 30µl, 40µl, 50 µl, 60µl, 70µl, 80µl, 90µl, 100µl, 200µl in distilled water. Further, 0.1ml from MRSA physiological broth saline of turbidity 0.5 McFarland standard measured at 600nm, which gives an approximate number of cells 1.5×10^8 CFU/ml, was diffused by a sterile diffuser on MHA plates. Pores of 6mm diameter were then made in each plate with a sterile cork perforator. The pores were then filled with the addition of 50µl of each concentration prepared from standard reuterin with distilled water as control. Petri-dishes were then incubated at 37°C for 24h. The diameters of bacterial inhibitory zones around pores were measured in millimetre units.

The cytotoxicity of the prepared reuterin dilutions to human red blood cells (RBCs) was tested in line with literature.¹ All data was analyzed with SPSS version 23.

Results

A total of 62 swabs were taken from the necrotic lesions of type 2 diabetes mellitus (T2DM) patients with diabetic foot ulcers (DFUs) under the supervision of a physician. The mean age of the patients was 46 ± 3 years and mean duration of DFIs 14 ± 1.5 years. Of the total isolates, 13(21%) were found to have *S. aureus* infections and of these, 9(69.2%) gave mauve to purple colour on staphylococcus chromogenic agar, which was then genetically confirmed as MRSA.

Table-1: Minimum inhibitory concentration (MIC) test of reuterin against methicillin-resistant staphylococcus aureus (MRSA).

Conc. µl/ml	Inhibition zone diameter (mm)	MIC value
control	0	
1	0	
5	0	
10	16	
20	21	
30	24	
40	27	10 µl/ml
50	28	
60	28	
70	29	
80	29	
90	30	
100	30	
200	31	




Figure-1: Agarose 1% gel electrophoresis for Staph 16SrDNA PCR products at position 756bp (Ladder: 100-1000bp).
DNA: Deoxyribonucleic acid, PCR: Polymerase chain reaction.




Figure-2: Agarose 1% gel electrophoresis for specific mecA gene products at position 310bp (Ladder: 100-1000bp).




Figure-3: Red blood cells (RBCs) under microscope (40X) after cytotoxicity test.

Electrophoresis showed that DNA gave single bands for *S. aureus* visualised under ultraviolet (UV) transilluminator .

Polymerase chain reaction (PCR) products for the amplification of Staph 16SrDNA under the UV transilluminator display all 13(21%) to be *S. aureus*, and gave a single band at position 756bp (Figure 1).Furthermore, 9(69.2%) isolates showed MRSA, and, as confirmed by the amplification of *mecA* genes, gave bands at 310bp (Figure 2).

The lowest reuterin concentration required to inhibit the growth of MRSA was 10µl/ml with inhibition zone diameter of 16mm, while inhibition of the zone increased with the increasing of concentration, and 10µl/ml was considered the MIC (Table).

Cytotoxicity test showed that the compound was not cytotoxic, and the RBCs settled at the bottom of the tubes, leaving a clear solution (Figure 3). They were intact and did not suffer from lysis during the 8-hour observation period.

Discussion

The current findings agreed with those of Gadban et al.¹³ who isolated *S. aureus* from DFUs at two local hospitals in Al-Basrah governorate of Iraq, but different from Osariemen et al. in Nigeria¹⁴. Perim et al. reported that *S. aureus* was predominant among bacteria isolated from DFUs in a Brazilian hospital¹⁵. This variation can be attributed partially to differences in associated microorganisms over time and geographic variation or type and severity of infection included in the studies¹⁶.

The current results related to agricultural phenotypic and microscopic diagnosis were in agreement with Merlino et al. who described the growth and identification of colonies¹⁷. Gaillot et al. reported that *S. aureus* isolates produced purple (positive) colonies usually 2-3mm in diameter after 24h of incubation with an halo mat surrounding the colonies of *S. aureus*.¹⁸

Based on Staph 16SrDNA gene, staphylococcus spp. was the most common and abundant bacterial isolate, which could indicate virulence factors for staphylococcus spp., particularly *S. aureus*, as a pathogenic bacteria in DFUs, as has been reported in other studies¹⁹.

The amplification of the genomic Staph 16SrDNA and *mecA* genes in all of the extracted DNA bacterial isolates confirmed that all of them were MRSA, while the PCR technique confirmed identification in addition to preventing bacterial loss²⁰.

MIC is the lowest concentration of an antimicrobial

metabolite that inhibits the visible development of a microorganism after an overnight incubation period²¹. Generally, as the reuterin concentrations increased, there was an increase in the diameters of the inhibitory zones, demonstrating the inhibitory effect of reuterin on *S. aureus*. This finding was consistent with earlier studies^{21, 22}.

In the current study, reuterin was significantly nontoxic. Sung et al. reported that the median lethal dose of reuterin in mice was estimated to be 7.55, while Chen et al. reported that the estimated median lethal dose of reuterin in mice ranged 260-320mg/kg²³. Also, 0.4-1.2mM of reuterin was enough to sterilise biological tissues contaminated by *Pseudomonas* (P.) *aeruginosa*, *Escherichia* (E.) *coli*, *S. aureus*, and *Bacillus* (B.) *subtilis* within 4 hours⁵. Chen et al. reported that mammalian cells were less sensitive to reuterin exposure when cytotoxicity was assessed in vitro using a mouse-derived established cell line of 3T3 fibroblasts, and a 7-day treatment with reuterin of rats infected with *Trypanosoma* (T.) *brucei* resulted in 68% reduction in parasitemia, and an increase in rat survival²³.

The long-term effects of reuterin on human health may occur after prolonged exposure to lower concentrations, while the metabolic fate of reuterin in humans is not completely known²⁴. Reuterin has been reported to exhibit moderate cytotoxicity in the human hepatoma cell line HepG2, and was generally recognised as a safe flavouring compound²⁵. More in-depth toxicological studies are needed to establish the safety profile before the compound can be recommended for use in various fields.

Limitation: The current study has limitations as the sample size was not calculated which could have affected the power of the study.

Conclusion

Reuterin was found to be a natural antimicrobial substance suitable for use to disinfect diabetic foot wounds from bacterial contamination and infection, especially those caused by MRSA.

Acknowledgements: We are grateful to all the patients and doctors who facilitated the study.

Disclaimer: None.

Conflict of Interest: None.

Source of Funding: None.

References

1. Vardakas KZ, Horianopoulou M, Falagas ME. Factors associated

with treatment failure in patients with diabetic foot infections: An analysis of data from randomized controlled trials. *Diabetes Res Clin Pract* 2008;80:344-51. doi: 10.1016/j.diabres.2008.01.009.

2. Amoako DG, Bester LA, Somboro AM, Baijnath S, Govind CN, Essack SY. Plasmid-mediated resistance and virulence mechanisms in the private health sector in KwaZulu-Natal, South Africa: An investigation of methicillin resistant *Staphylococcus aureus* (MRSA) clinical isolates collected during a three month period. *Int J Infect Dis* 2016;46:38-41. doi: 10.1016/j.ijid.2016.03.019.
3. Dunyach-Remy C, Ngba Essebe C, Sotto A, Lavigne JP. *Staphylococcus aureus* Toxins and Diabetic Foot Ulcers: Role in Pathogenesis and Interest in Diagnosis. *Toxins (Basel)* 2016;8:209. doi: 10.3390/toxins8070209.
4. Viswanathan V, Pendsey S, Radhakrishnan C, Rege TD, Ahdal J, Jain R. Methicillin-Resistant *Staphylococcus aureus* in Diabetic Foot Infection in India: A Growing Menace. *Int J Low Extrem Wounds* 2019;18:236-46. doi: 10.1177/1534734619853668.
5. Sung HW, Chen CN, Liang HF, Hong MH. A natural compound (reuterin) produced by *Lactobacillus reuteri* for biological-tissue fixation. *Biomaterials* 2003;24:1335-47. doi: 10.1016/s0142-9612(02)00509-4.
6. Vollenweider S, Lacroix C. 3-hydroxypropionaldehyde: applications and perspectives of biotechnological production. *Appl Microbiol Biotechnol* 2004;64:16-27. doi: 10.1007/s00253-003-1497-y.
7. Arqués JL, Rodríguez E, Nuñez M, Medina M. Inactivation of Gram-negative pathogens in refrigerated milk by reuterin in combination with nisin or the lactoperoxidase system. *Eur Food Res Technol* 2008;227:77-82.
8. Al-Tameemi KA, Hraishawi RM, Aaz FL. Isolation, identification and evaluation of resistance of bacterial isolates from patients with tonsillitis. *Ann Trop Med Public Health* 2020;23:10.
9. Zhang K, Sparling J, Chow BL, Elsayed S, Hussain Z, Church DL, et al. New quadriplex PCR assay for detection of methicillin and mupirocin resistance and simultaneous discrimination of *Staphylococcus aureus* from coagulase-negative staphylococci. *J Clin Microbiol* 2004;42:4947-55. doi: 10.1128/JCM.42.11.4947-4955.2004.
10. Eed EM, Ghonaim MM, Hussein YM, Al-Shehri SS, Khalifa AS. Molecular characterisation of Pantone-Valentine leucocidin-producing methicillin-resistant *Staphylococcus aureus* clones isolated from the main hospitals in Taif, KSA. *Indian J Med Microbiol* 2016;34:476-82. doi: 10.4103/0255-0857.195364.
11. Mohapatra DP, Thakur V, Brar SK. Antibacterial efficacy of raw and processed honey. *Biotechnol Res Int* 2011;2011:e917505. doi: 10.4061/2011/917505.
12. Balakrishnan S, Santhanam P, Srinivasan M. Larvicidal potency of marine actinobacteria isolated from mangrove environment against *Aedes aegypti* and *Anopheles stephensi*. *J Parasit Dis* 2017;41:387-94. doi: 10.1007/s12639-016-0812-3.
13. Gadban TH, Al-Amara SS, Jasim HA. Screening the frequency of pantone-valentine leukocidin (pvl) gene between methicillin resistant *Staphylococcus aureus* isolated from diabetic foot patients in Al-Basrah governorate, south of Iraq. *Sys Rev Pharma* 2020;11:285-90.
14. Osariemen IJ, Olowu SS, Adebo E, Omon EE, Victoria O, Imuetinyan EJ, Adesewa E. Aerobic bacteria associated with diabetic wounds in patients attending clinic in a rural community in Nigeria. *Glo Res J Micro* 2013;3:8-12.
15. Perim MC, Borges Jda C, Celeste SR, Orsolin Ede F, Mendes RR, Mendes GO, et al. Aerobic bacterial profile and antibiotic resistance in patients with diabetic foot infections. *Rev Soc Bras Med Trop* 2015;48:546-54. doi: 10.1590/0037-8682-0146-2015.
16. Kavitha Y. & Mohiddin S.K. Bacteriological profile of diabetic foot

- infections in a tertiary care teaching hospital. *Indian J Basic Appl Med Res* 2014;3:260-6.
17. Merlino J, Leroi M, Bradbury R, Veal D, Harbour C. New chromogenic identification and detection of *Staphylococcus aureus* and methicillin-resistant *S. aureus*. *J Clin Microbiol* 2000;38:2378-80. doi: 10.1128/JCM.38.6.2378-2380.2000.
 18. Gaillot O, Wetsch M, Fortineau N, Berche P. Evaluation of CHROMagar *Staph. aureus*, a new chromogenic medium, for isolation and presumptive identification of *Staphylococcus aureus* from human clinical specimens. *J Clin Microbiol* 2000;38:1587-91. doi: 10.1128/JCM.38.4.1587-1591.2000.
 19. Sadeghpour Heravi F, Zakrzewski M, Vickery K, G Armstrong D, Hu H. Bacterial Diversity of Diabetic Foot Ulcers: Current Status and Future Prospectives. *J Clin Med* 2019;8:1935. doi: 10.3390/jcm8111935.
 20. Abd Ellatif S, Abed NN, Mahfouz AY, Desouky EM, Abd El Hamid DK. Production, purification and identification of Glycine, N-(*m*-anisoyl)-methyl ester from *Pseudomonas aeruginosa* with antimicrobial and anticancer activities. *Kuwait J Sci* 2021;48:1-12.
 21. Niamah AK, Abdulmutaleb AM, Hussain NA. Antibacterial spectrum of produced reuterin from new isolates of *Lactobacillus reuteri*. *J Microbiol Biotechnol Food Sci* 2020;10:134-9. doi: 10.15414/jmbfs.2020.10.1.134-139.
 22. Helal MM, Hashem AM, Ghobashy MO, Shalaby AS. Some physiological and biological studies on reuterin production from *Lactobacillus reuteri*. *J Probiotics Health* 2016;4:10-4172.
 23. Chen CN, Sung HW, Liang HF, Chang WH. Feasibility study using a natural compound (reuterin) produced by *Lactobacillus reuteri* in sterilizing and crosslinking biological tissues. *J Biomed Mater Res* 2002;61:360-9. doi: 10.1002/jbm.10153.
 24. Avila M, Gómez-Torres N, Hernández M, Garde S. Inhibitory activity of reuterin, nisin, lysozyme and nitrite against vegetative cells and spores of dairy-related *Clostridium* species. *Int J Food Microbiol* 2014;172:70-5. doi: 10.1016/j.ijfoodmicro.2013.12.002.
 25. Fernández-Cruz ML, Martín-Cabrejas I, Pérez-del Palacio J, Gaya P, Díaz-Navarro C, Navas JM, Medina M, Arqués JL. In vitro toxicity of reuterin, a potential food biopreservative. *Food Chem Toxicol* 2016;96:155-9. doi: 10.1016/j.fct.2016.08.002.
-